Xencor Swings to $39.4M Profit as Royalties and Milestones Lift Revenue 5x
XNCR has more than doubled off its 52-week low of $10.375.
Summary
Xencor flipped to a $39.4 million profit, or $0.50 per diluted share, in Q3 2026 from a $6.0 million loss a year earlier, as revenue jumped to $116.5 million from $21.0 million on Alexion and Incyte royalties plus an Astellas milestone. Cash and marketable securities stood at $555.7 million at September 30, and management guided to $480-500 million at year-end with funding into 2029 — no financing need in sight. The quarter also carried partnership momentum: Astellas dosed the first patient in the ASP2138 Phase 3, triggering a $25.0 million payment, and Zenas' partner Bristol Myers Squibb filed a Japan MAA for obexelimab, adding $2.5 million. R&D spending rose to $84.3 million from $54.4 million as the XmAb819 program scales toward a planned Phase 3 in advanced ccRCC, following the October ESMO data and 400 mcg/kg dose selection. Near-term readout: early plamotamab dose-escalation data in rheumatoid arthritis at ACR on November 9.
At the time of this announcement, XNCR was trading at $34.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $10.38 to $35.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.